Literature DB >> 17000465

The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells.

Tetyana Duka1, Anita Sidhu.   

Abstract

Alzheimer's disease (AD) is characterized, in part, by intracellular neurofibrillary tangles composed of hyperphosphorylated filamentous aggregates of the microtubule-associated protein, Tau. Such hyperphosphorylated Tau is also found in Lewy bodies (LBs), and cytoplasmic inclusion bodies in certain forms of Parkinson's disease (PD). Further, LBs also contain aggregates of alpha-synuclein (alpha-Syn), also a microtubule-associated protein, which has been linked to the genesis of PD. To investigate a specific correlation between Tau phosphorylation and alpha-Syn, we generated a SH-SY5Y cell line that stably expresses human wild type alpha-Syn. Protein expression levels in the stably transfected cell line (SHalpha-Syn) were within the physiological range of alpha-Syn expression found in Substantia nigra. We show here, in the MPP+ (1-methyl-4-phenylpyridinium ion) cell model of parkinsonism, a time- and dose-dependent increase in the hyperphosphorylation of Tau at pSer396/404 (PHF-1-reactive Tau, p-Tau), concomitant with increased accumulation of alpha-Syn, upon treatment of cells with the neurotoxin. This increase in p-Tau was strictly dependent on the presence of alphaSyn, since in transfected cells not expressing any alpha-Syn, MPP+ failed to induce an increase in PHF-1-reactive Tau. The production of p-Tau caused increased cytotoxicity as indexed by reduced cell viability. Moreover, in the absence of alpha-Syn, the cells were more resistant to MPP+ -induced cell death. The increased levels of both p-Tau and alpha-Syn led to diminished levels of these proteins associated with the cytoskeleton, which was accompanied by enhanced presence of the proteins in the cytoskeletal-free fractions. These data indicate that alpha-Syn and p-Tau modulate the pathogenicity of one another, suggesting a novel convergent mechanism of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000465     DOI: 10.1007/bf03033329

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  50 in total

Review 1.  Following the leader: fibrillization of alpha-synuclein and tau.

Authors:  Mark Frasier; Benjamin Wolozin
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

Review 3.  The role of alpha-synuclein in both neuroprotection and neurodegeneration.

Authors:  Anita Sidhu; Christophe Wersinger; Charbel E-H Moussa; Philippe Vernier
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

4.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

5.  Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Neurosci Lett       Date:  2002-03-08       Impact factor: 3.046

6.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

7.  Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.

Authors:  Günter U Höglinger; Géraldine Carrard; Patrick P Michel; Fadia Medja; Anne Lombès; Merle Ruberg; Bertrand Friguet; Etienne C Hirsch
Journal:  J Neurochem       Date:  2003-09       Impact factor: 5.372

8.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells.

Authors:  Christophe Wersinger; Melanie Banta; Anita Sidhu
Journal:  Neurosci Lett       Date:  2004-03-25       Impact factor: 3.046

10.  17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions.

Authors:  Kirk C Wilhelmsen; Mark S Forman; Howard J Rosen; Loren I Alving; Jill Goldman; Jennie Feiger; James V Lee; Samantha K Segall; Joel H Kramer; Catherine Lomen-Hoerth; Katherine P Rankin; Julene Johnson; Heidi S Feiler; Michael W Weiner; Virginia M-Y Lee; John Q Trojanowski; Bruce L Miller
Journal:  Arch Neurol       Date:  2004-03
View more
  22 in total

1.  Induction of heat shock proteins in differentiated human and rodent neurons by celastrol.

Authors:  Ari M Chow; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

2.  The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism.

Authors:  Irmgard Paris; Jorge Lozano; Sergio Cardenas; Carolina Perez-Pastene; Katherine Saud; Patricio Fuentes; Pablo Caviedes; Alexies Dagnino-Subiabre; Rita Raisman-Vozari; Takeshi Shimahara; John P Kostrzewa; David Chi; Richard M Kostrzewa; Raul Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

3.  Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line.

Authors:  Irmgard Paris; Carolina Perez-Pastene; Sergio Cardenas; Patricio Iturriaga-Vasquez; Patricio Iturra; Patricia Muñoz; Eduardo Couve; Pablo Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2010-01-20       Impact factor: 3.911

4.  Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Authors:  Jonathan Wills; Jessica Jones; Thomas Haggerty; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  Exp Neurol       Date:  2010-06-28       Impact factor: 5.330

5.  Ankyrin repeat and BTB/POZ domain containing protein-2 inhibits the aggregation of alpha-synuclein: implications for Parkinson's disease.

Authors:  Avik Roy; Kalipada Pahan
Journal:  FEBS Lett       Date:  2013-09-25       Impact factor: 4.124

6.  Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.

Authors:  Thomas Haggerty; Joel Credle; Olga Rodriguez; Jonathan Wills; Adam W Oaks; Eliezer Masliah; Anita Sidhu
Journal:  Eur J Neurosci       Date:  2011-04-01       Impact factor: 3.386

7.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

8.  Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Authors:  Tetyana Duka; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  FASEB J       Date:  2009-04-15       Impact factor: 5.191

9.  Molecular and neurochemical mechanisms in PD pathogenesis.

Authors:  Irmgard Paris; Jorge Lozano; Carolina Perez-Pastene; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2009-05-20       Impact factor: 3.911

10.  Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Authors:  Adam W Oaks; Maya Frankfurt; David I Finkelstein; Anita Sidhu
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.